FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040876925> ?p ?o ?g. }

• W2040876925 endingPage "240" @default.
• W2040876925 startingPage "234" @default.
• W2040876925 abstract "Background Glycoprotein (GP) IIb/IIIa antagonists are potent inhibitors of thrombocyte aggregation and thrombus formation. Several large-scale randomized studies for prevention of thrombotic complications have shown their potential to reduce these complications in patients undergoing percutaneous transluminal coronary angioplasty (PTCA). It was the purpose of this observational trial to assess the frequency and efficacy of primary GP IIb/IIIa antagonist therapy as a bailout procedure for the prevention of threatened or abrupt vessel closure in patients after conventional balloon angioplasty. Methods And Results From January 1995 to December 1996, PTCA was performed in 1332 consecutive patients with coronary artery disease. Overall, threatened or abrupt vessel closure was observed in 63 (4.7%) patients of the patient population. In these patients, abciximab was administered (0.25 mg/kg body weight intravenous bolus, followed by a 12-hour infusion at 10 μg/min). Repeat PTCA was performed shortly after the administration of the abciximab bolus to achieve an optimal flow at the time of active GP IIb/IIIa therapy. One day after intervention, early follow-up angiography was performed. Follow-up after 1 year included the clinical status of all patients and, if possible, control angiography. Overall, the preintervention minimum lumen diameter (MLD) measured 0.74 ± 0.27 mm and the diameter stenosis was 75% ± 24%. The postintervention MLD increased to 2.60 ± 0.55 mm, and the diameter stenosis decreased to 24% ± 22%. At 24-hour angiographic follow-up, the MLD decreased to 2.47 ± 0.49 mm and the diameter stenosis increased to 28% ± 24%, correspondingly. The thrombus score decreased from 2.8 ± 1.5 before abciximab treatment to 0.88 ± 0.81 after abciximab treatment, and Thrombolysis In Myocardial Infarction flow grade increased from 2.1 ± 1.1 to 2.9 ± 0.3. In-hospital events occurred in 2 patients. Both patients had to undergo emergency coronary artery bypass grafting (1 of these patients died). During long-term follow-up, there were 10 clinical events (1 death, 3 repeat PTCA, and 6 coronary artery bypass graft operations for restenosis at the target lesion site). The cumulative event rate after 1 year (including acute and follow-up events) for both the total group and for the target vessel was 19%. Conclusions The results of this study demonstrate that GP IIb/IIIa antagonists are able to prevent vessel occlusion after PTCA complicated by subsequent threatened or abrupt vessel closure. In these situations, GP IIb/IIIa antagonists provide effective treatment for the reduction of thrombus at the target lesion site, which constitutes a second key element for threatened or abrupt vessel occlusion. (Am Heart J 1999;137:234-40.)" @default.
• W2040876925 created "2016-06-24" @default.
• W2040876925 creator A5025528254 @default.
• W2040876925 creator A5051025215 @default.
• W2040876925 creator A5057323746 @default.
• W2040876925 creator A5059069616 @default.
• W2040876925 creator A5066969746 @default.
• W2040876925 creator A5071203370 @default.
• W2040876925 creator A5079423106 @default.
• W2040876925 date "1999-02-01" @default.
• W2040876925 modified "2023-09-27" @default.
• W2040876925 title "Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty" @default.
• W2040876925 cites W1709286512 @default.
• W2040876925 cites W173676251 @default.
• W2040876925 cites W1979863435 @default.
• W2040876925 cites W1981647960 @default.
• W2040876925 cites W2005266907 @default.
• W2040876925 cites W2010678261 @default.
• W2040876925 cites W2024508062 @default.
• W2040876925 cites W2024531696 @default.
• W2040876925 cites W2035279091 @default.
• W2040876925 cites W2037135708 @default.
• W2040876925 cites W2046902524 @default.
• W2040876925 cites W2050069100 @default.
• W2040876925 cites W2063477544 @default.
• W2040876925 cites W2069217073 @default.
• W2040876925 cites W2079863654 @default.
• W2040876925 cites W2085869089 @default.
• W2040876925 cites W2087561093 @default.
• W2040876925 cites W2107050302 @default.
• W2040876925 cites W2131384376 @default.
• W2040876925 cites W2136249461 @default.
• W2040876925 cites W2148129851 @default.
• W2040876925 cites W2157955461 @default.
• W2040876925 cites W217496567 @default.
• W2040876925 cites W2230838014 @default.
• W2040876925 cites W2323785475 @default.
• W2040876925 cites W2395313915 @default.
• W2040876925 cites W2397283806 @default.
• W2040876925 cites W2493925730 @default.
• W2040876925 cites W3022148767 @default.
• W2040876925 doi "https://doi.org/10.1053/hj.1999.v137.93038" @default.
• W2040876925 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9924156" @default.
• W2040876925 hasPublicationYear "1999" @default.
• W2040876925 type Work @default.
• W2040876925 sameAs 2040876925 @default.
• W2040876925 citedByCount "13" @default.
• W2040876925 countsByYear W20408769252014 @default.
• W2040876925 crossrefType "journal-article" @default.
• W2040876925 hasAuthorship W2040876925A5025528254 @default.
• W2040876925 hasAuthorship W2040876925A5051025215 @default.
• W2040876925 hasAuthorship W2040876925A5057323746 @default.
• W2040876925 hasAuthorship W2040876925A5059069616 @default.
• W2040876925 hasAuthorship W2040876925A5066969746 @default.
• W2040876925 hasAuthorship W2040876925A5071203370 @default.
• W2040876925 hasAuthorship W2040876925A5079423106 @default.
• W2040876925 hasConcept C126322002 @default.
• W2040876925 hasConcept C141071460 @default.
• W2040876925 hasConcept C164705383 @default.
• W2040876925 hasConcept C2777871224 @default.
• W2040876925 hasConcept C2778283817 @default.
• W2040876925 hasConcept C2778583881 @default.
• W2040876925 hasConcept C2780007028 @default.
• W2040876925 hasConcept C2780326628 @default.
• W2040876925 hasConcept C2780400711 @default.
• W2040876925 hasConcept C2908647359 @default.
• W2040876925 hasConcept C500558357 @default.
• W2040876925 hasConcept C71924100 @default.
• W2040876925 hasConcept C99454951 @default.
• W2040876925 hasConceptScore W2040876925C126322002 @default.
• W2040876925 hasConceptScore W2040876925C141071460 @default.
• W2040876925 hasConceptScore W2040876925C164705383 @default.
• W2040876925 hasConceptScore W2040876925C2777871224 @default.
• W2040876925 hasConceptScore W2040876925C2778283817 @default.
• W2040876925 hasConceptScore W2040876925C2778583881 @default.
• W2040876925 hasConceptScore W2040876925C2780007028 @default.
• W2040876925 hasConceptScore W2040876925C2780326628 @default.
• W2040876925 hasConceptScore W2040876925C2780400711 @default.
• W2040876925 hasConceptScore W2040876925C2908647359 @default.
• W2040876925 hasConceptScore W2040876925C500558357 @default.
• W2040876925 hasConceptScore W2040876925C71924100 @default.
• W2040876925 hasConceptScore W2040876925C99454951 @default.
• W2040876925 hasIssue "2" @default.
• W2040876925 hasLocation W20408769251 @default.
• W2040876925 hasLocation W20408769252 @default.
• W2040876925 hasOpenAccess W2040876925 @default.
• W2040876925 hasPrimaryLocation W20408769251 @default.
• W2040876925 hasRelatedWork W2000740588 @default.
• W2040876925 hasRelatedWork W2006237258 @default.
• W2040876925 hasRelatedWork W2011887025 @default.
• W2040876925 hasRelatedWork W2049397185 @default.
• W2040876925 hasRelatedWork W2125861529 @default.
• W2040876925 hasRelatedWork W2139306977 @default.
• W2040876925 hasRelatedWork W2399063111 @default.
• W2040876925 hasRelatedWork W2619044267 @default.
• W2040876925 hasRelatedWork W3014667322 @default.
• W2040876925 hasRelatedWork W3101987106 @default.
• W2040876925 hasVolume "137" @default.

• next